About Jeuveau®
Jeuveau® (prabotulinumtoxinA-xvfs) injection is an FDA-approved prescription medicine (AKA neuromodular, AKA neurotoxin, AKA tox) used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
When expertly injected for frown lines or “11’s”, Jeuveau® temporarily prevents your nerves from telling your muscles to flex or contract. This process smooths the appearance of “dynamic” frown lines — like the ones from years of frowning at your phone.
Best Candidates
The best candidates for Jeuveau injections are in good health who show the following signs:
Dynamic wrinkles
Smile and/or frown lines
Lines around the eyes (“crow’s feet”)
What To Expect
The doctor will look at the quantity, depth, and location of your dynamic wrinkles to mark the areas of the muscles of the face that will be treated. With an ultra-fine syringe, Juveau will be carefully injected into the marked areas. Most patients report mild discomfort when the needle pierces the skin, but numbing creams and cold compresses can be used to make your treatment more comfortable.
Other Considerations
Besides some swelling and redness for 3-4 hours, you should be able to return to your regular activities after the injection. We encourage all of our Jeuveau patients to avoid exercise for 24 hours and to sleep upright the first night after the treatment. Complete results after Jeuveau are visible (smoother forehead and diminished wrinkles) in about 5-7 days. Many patients feel that Jeuveau treatments make their skin look radiant, they feel younger, and look well rested.
Ageless Expressions
In clinical trials, Jeuveau was shown to temporarily improve the appearance of moderate to severe frown lines. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30. But that's not all. In a study conducted in Europe and Canada, 54% of patients had visible results as early as 2 days after treatment.* And at 5 months after treatment, 38% of patients had visible results with Jeuveau**
